Exclusive: Gulliver Waite signed up after antidepressants and talking therapies failed to alleviate clinical depression

• Low participation in medical trials puts millions of young people at risk

Millions of young people risk missing out on new treatments for health conditions and having to use medicines that are unsafe, ineffective or inappropriate because so few take part in medical research. One of those bucking the trend explains why he signed up to a study and how it transformed his life.

Gulliver Waite was diagnosed with clinical depression at 19. For years, he struggled with extremely low mood, anxiety, frequent panic attacks and occasional paranoia.

Women’s health academics at UCL call for national education programme to combat misinformation and unregulated advice

Millions of women are being exploited by a “menopause gold rush” as companies, celebrities and influencers take advantage of a “dearth” of reliable information on the issue, experts have said.

Healthcare companies and content creators saw menopause as a “lucrative market” and were trying to profit from gaps in public knowledge, women’s health academics at UCL said.

Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers

Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks.

Head and neck cancer is the world’s sixth most common form of the disease. If it spreads or comes back after standard treatment, patients may be offered immunotherapy and platinum chemotherapy. But if this fails, there is often little else doctors can do.